HUMMINGBIRD Pediatric COVID-19 vaccine Study
Overview
Morehouse School of Medicine is participating in a new clinical trial called the HUMMINGBIRD study, a Phase 2/3 study to evaluate the safety and immunogenicity of an investigational vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in pediatric participants.
Is it free to participate in a study?
There will be no charge to study participants for their participation in this study. The investigational vaccine and placebo, study-related procedures, and study visits will be provided at no charge. Study transportation may be provided (based on availability), and participants will be compensated for time and study-related travel.
Who can participate?
Participants must be 6 months to < 12 years of age
Be healthy or medically stable
Should not have prior administration of a
coronavirus vaccine or previous lab-confirmed diagnosis of SARS-CoV-2 infection
or
COVID-19
HUMMINGBIRD study enrollment is currently active, and visits are conducted at Clinical Research Center at Morehouse School of Medicine.
If you or someone you know is interested, please have them fill out the MSM Interest Survey or just contact us at 
